Shopping Cart

Author: Nicholas Alan Clayton

SPAC-morning-roundup
new-spac

New SPAC: Willow Lane Acquisition Corp. (WLACU) Files for $110M IPO

Oct 4, 2024 Headline Post, INTEL, New S-1 Filings by Nicholas Alan Clayton
Willow Lane (NASDAQ:WLACU) has filed for a $110 million SPAC to be the latest repeat SPAC team returning to the market with the help of underwriter BTIG. BTIG is, in fact, leading recent underwriter activity with four new SPACs filed since the August 1, while no other firm has been left lead for more than
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
SPAC-morning-roundup

Morning SPAC News Roundup: October 4, 2024

Oct 4, 2024 SPACs in the News by Nicholas Alan Clayton
At the SPAC of Dawn While SPACs settle into a slight pause through Rosh Hashanah, de-SPACs are also entering another period of holiday-based trading patterns. Traders following the usual “Sell in May and Go Away” pattern this year would have missed out on a major late-summer market rally. But, stocks may now feel the effects
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
SPAC-morning-roundup
china pic

Iron Horse Acquisitions (IROH) to Combine with China Food Investment in $523M Deal

Oct 2, 2024 Deal Announcements & Amendments, Headline Post, INTEL by Nicholas Alan Clayton
Iron Horse (NASDAQ:IROH) has entered into a definitive agreement to combine with healthy food firm China Food Investment at a post-transaction enterprise value of $523 million. Hong Kong-based China Food investment distributes and advocates for healthy food products in Asia. The combined company is expected to trade on the Nasdaq once the deal is completed
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
SPAC-morning-roundup
new-spac
SPAC-morning-roundup

Morning SPAC News Roundup: October 1, 2024

Oct 1, 2024 SPACs in the News by Nicholas Alan Clayton
At the SPAC of Dawn De-SPACs have long been targets of short-selling and the turnover that occurs after each completed deal provides some seemingly obvious opportunities for the shorts to exploit. Shorts have also tended to pile on companies following a disappointing round of earnings or the sort of profitability concerns that plagued many growth-stage
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
lock-ups

SPAC Lock-Up Expirations to Watch in October 2024

Sep 30, 2024 Headline Post, INTEL by Nicholas Alan Clayton
October is likely to be the quietest month of 2024 in terms of SPAC partners coming unglued from their lock-up agreements, and it comes right on the heels of the most-watched lock-up expiry in quite some time. Although Trump Media’s (NASDAQ:DJT) unlocking did not release the same sparks that might have been anticipated, it did
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
new-spac

New SPAC: Jackson Acquisition Company II (JACS.U) Files for $200M IPO

Sep 30, 2024 Headline Post, INTEL, New S-1 Filings by Nicholas Alan Clayton
Jackson II (NYSE:JACS.U) has filed for a $200 million SPAC with improved terms over the team’s last vehicle, which liquidated in 2023 without a having signed a deal. This SPAC would have some structures from the standard set of mid-2024 filings as it will not overfund its trust with $10.00 per share in the account
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
SPAC-morning-roundup
SPAC-morning-roundup
SPAC-morning-roundup
new-spac

New SPAC: Charlton Aria Acquisition Corporation (CHARU) Files for $75M IPO

Sep 25, 2024 Headline Post, INTEL, New S-1 Filings by Nicholas Alan Clayton
Charlton Aria (NASDAQ:CHARU) helps pick up the pace in new SPAC filings as its bid for a $75 million IPO becomes the fourth new entry in the past week after no SPACs filed in the first half of the September. It would also be the third SPAC brought to market by Clear Street, which debuted
Read More
To access this post, you must purchase 1 - User: Monthly Plan.

Breeze Holdings Acquisition Corp. (BRZH) to Combine with YD Biopharma in $694M Deal

Sep 25, 2024 Deal Announcements & Amendments, Headline Post, INTEL by Nicholas Alan Clayton
Breeze Holdings Acquisition Corp. (OTC:BRZH) has entered into a definitive agreement to combine with drug developer YD Biopharma at an enterprise value of $694 million. Taipei-based YD is developing a trio of treatment candidates meant to treat some eye conditions and screen for pancreatic and breast cancer, whose patents it has under license. The combined
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
SPAC-morning-roundup
digitial world dwac-tmtg logo

Trump Media (DJT) Rebounding from Lock-Up Expiry Dip

Sep 24, 2024 Headline Post, INTEL by Nicholas Alan Clayton
Company and sponsor shareholders in this year’s buzziest de-SPAC have now been set free from the most anticipated early lock-up expiration release, but the change has arguably so far been less dramatic than the buildup. The parties in question are of course Trump Media (NASDAQ:DJT) and holders of Digital World promote shares and it finished
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
new-spac

New SPAC: Cohen Circle Acquisition Corp. I (CCIRU) Files for $200M IPO

Sep 24, 2024 Headline Post, INTEL, New S-1 Filings by Nicholas Alan Clayton
Cohen Circle I (NASDAQ:CCIRU) became the second serial SPAC team to return via a new S-1 filing Friday evening and it brings another strong team with interesting terms to what should be an intriguing fourth quarter ecosystem of SPACs searching for high-profile deals. In its case, the Cohen Circle I is aiming to raise $200
Read More
To access this post, you must purchase 1 - User: Monthly Plan.
SPAC-morning-roundup

Morning SPAC News Roundup: September 24, 2024

Sep 24, 2024 SPACs in the News by Nicholas Alan Clayton
At the SPAC of Dawn Congress hasn’t done much for SPACs in some time, but it appears poised to boost at least one category of transactions in the coming weeks. The House yesterday passed a wide-ranging bill yesterday that extends and clarifies some of the exclusivity protections and preferential review processes for certain drug candidates
Read More
To access this post, you must purchase 1 - User: Monthly Plan.